Protein structure and phenotypic analysis of pathogenic and population missense variants inSTXBP1
Open Access
- 20 June 2017
- journal article
- research article
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 5 (5) , 495-507
Abstract
Background Syntaxin‐binding protein 1, encoded by STXBP1, is highly expressed in the brain and involved in fusing synaptic vesicles with the plasma membrane. Studies have shown that pathogenic loss‐of‐function variants in this gene result in various types of epilepsies, mostly beginning early in life. We were interested to model pathogenic missense variants on the protein structure to investigate the mechanism of pathogenicity and genotype–phenotype correlations. Methods We report 11 patients with pathogenic de novo mutations in STXBP1 identified in the first 4293 trios of the Deciphering Developmental Disorder (DDD) study, including six missense variants. We analyzed the structural locations of the pathogenic missense variants from this study and the literature, as well as population missense variants extracted from Exome Aggregation Consortium (ExAC). Results Pathogenic variants are significantly more likely to occur at highly conserved locations than population variants, and be buried inside the protein domain. Pathogenic mutations are also more likely to destabilize the domain structure compared with population variants, increasing the proportion of (partially) unfolded domains that are prone to aggregation or degradation. We were unable to detect any genotype–phenotype correlation, but unlike previously reported cases, most of the DDD patients with STXBP1 pathogenic variants did not present with very early‐onset or severe epilepsy and encephalopathy, though all have developmental delay with intellectual disability and most display behavioral problems and suffered seizures in later childhood. Conclusion Variants across STXBP1 that cause loss of function can result in severe intellectual disability with or without seizures, consistent with a haploinsufficiency mechanism. Pathogenic missense mutations act through destabilization of the protein domain, making it prone to aggregation or degradation. The presence or absence of early seizures may reflect ascertainment bias in the literature as well as the broad recruitment strategy of the DDD study.Keywords
Funding Information
- Health Innovation Challenge Fund (HICF-1009-003)
- Wellcome Trust (WT098051)
This publication has 71 references indexed in Scilit:
- Patterns and rates of exonic de novo mutations in autism spectrum disordersNature, 2012
- Munc13 mediates the transition from the closed syntaxin–Munc18 complex to the SNARE complexNature Structural & Molecular Biology, 2011
- Excess of De Novo Deleterious Mutations in Genes Associated with Glutamatergic Systems in Nonsyndromic Intellectual DisabilityThe American Journal of Human Genetics, 2011
- Possible roles for Munc18-1 domain 3a and Syntaxin1 N-peptide and C-terminal anchor in SNARE complex formationProceedings of the National Academy of Sciences, 2010
- At the junction of SNARE and SM protein functionCurrent Opinion in Cell Biology, 2010
- SNARE bundle and syntaxin N-peptide constitute a minimal complement for Munc18-1 activation of membrane fusionJournal of Cell Biology, 2010
- Binding of Munc18-1 to Synaptobrevin and to the SNARE Four-Helix BundleBiochemistry, 2010
- Functional annotations improve the predictive score of human disease-related mutations in proteinsHuman Mutation, 2009
- Munc18a controls SNARE assembly through its interaction with the syntaxin N‐peptideThe EMBO Journal, 2008
- Munc18-1 binds directly to the neuronal SNARE complexProceedings of the National Academy of Sciences, 2007